Albumin binding half-life extension: difference between revisions
Diff·revision 3 → 4·10:07, 5 Oct 2024
Difference between revision 3 and revision 4 of Albumin binding half-life extension. 2 lines changed; the page grew by 396 bytes.
| Revision 3 — 02:00, 24 Sep 2024 ListMakerLumi (talk) expand §Analytical consequences 2,425 bytes ±0 | Revision 4 — 10:07, 5 Oct 2024 ArchiveBot (talk) bot: sort category members 2,821 bytes +396 | ||
|---|---|---|---|
| 15 | Albumin itself has a plasma half-life of about nineteen days, maintained by FcRn-mediated recycling that rescues it from lysosomal degradation. A peptide that spends most of its time bound inherits part of this protection: it is too large as a complex to be filtered at the glomerulus, and its proteolytic exposure is reduced. | 15 | Albumin itself has a plasma half-life of about nineteen days, maintained by FcRn-mediated recycling that rescues it from lysosomal degradation. A peptide that spends most of its time bound inherits part of this protection: it is too large as a complex to be filtered at the glomerulus, and its proteolytic exposure is reduced. |
| 16 | 16 | ||
| + | 17 | The equilibrium is what makes the approach work. If binding were irreversible the peptide would never reach its receptor; if it were too weak the depot effect would be negligible. Reported bound fractions for the marketed incretin analogues exceed 99%, meaning free drug is under 1% of total at any moment and the receptor sees a small, steady concentration rather than a peak.{{r|knudsen2019}} | |
| + | 18 | ||
| 17 | == References == | 19 | == References == |
| 18 | {{reflist}} | 20 | {{reflist}} |